260 related articles for article (PubMed ID: 24947987)
1. PET/CT imaging in cancer: current applications and future directions.
Farwell MD; Pryma DA; Mankoff DA
Cancer; 2014 Nov; 120(22):3433-45. PubMed ID: 24947987
[TBL] [Abstract][Full Text] [Related]
2. The pivotal role of FDG-PET/CT in modern medicine.
Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
[TBL] [Abstract][Full Text] [Related]
3. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
4. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
[TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
6. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
7. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography/computed tomography: the current technology and applications.
Mittra E; Quon A
Radiol Clin North Am; 2009 Jan; 47(1):147-60. PubMed ID: 19195540
[TBL] [Abstract][Full Text] [Related]
9. Fundamentals of PET and PET/CT imaging.
Basu S; Kwee TC; Surti S; Akin EA; Yoo D; Alavi A
Ann N Y Acad Sci; 2011 Jun; 1228():1-18. PubMed ID: 21718318
[TBL] [Abstract][Full Text] [Related]
10. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
[TBL] [Abstract][Full Text] [Related]
11. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
12. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
13. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
[TBL] [Abstract][Full Text] [Related]
14. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
16. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
17. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
Kim YI; Kim SK; Paeng JC; Lee HY
Eur J Radiol; 2014 Jan; 83(1):231-5. PubMed ID: 24290142
[TBL] [Abstract][Full Text] [Related]
18. PET and PET/CT in pediatric oncology.
Jadvar H; Connolly LP; Fahey FH; Shulkin BL
Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
[TBL] [Abstract][Full Text] [Related]
19. Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck.
Zimmer LA; Branstetter BF; Nayak JV; Johnson JT
Laryngoscope; 2005 Nov; 115(11):2029-34. PubMed ID: 16319618
[TBL] [Abstract][Full Text] [Related]
20. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]